Edition:
United Kingdom

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

8.75USD
19 Apr 2018
Change (% chg)

$-0.17 (-1.91%)
Prev Close
$8.92
Open
$8.91
Day's High
$9.07
Day's Low
$8.63
Volume
45,087
Avg. Vol
59,011
52-wk High
$23.68
52-wk Low
$7.85

Chart for

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing... (more)

Overall

Beta: --
Market Cap(Mil.): $317.10
Shares Outstanding(Mil.): 16.90
Dividend: --
Yield (%): --

Financials

  PTGX.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -3.00 -- --
ROI: -116.32 1.58 14.38
ROE: -643.53 2.41 16.07

BRIEF-Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100

* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS

26 Mar 2018

BRIEF-Protagonist Therapeutics Q4 Loss Per Share $0.15

* PROTAGONIST THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

07 Mar 2018

BRIEF-FDA Grants Orphan Drug Designation For Protagonist Therapeutics' PTG-300

* FDA GRANTS ORPHAN DRUG DESIGNATION FOR PROTAGONIST THERAPEUTICS' PTG-300 FOR THE TREATMENT OF BETA-THALASSEMIA Source text for Eikon: Further company coverage:

06 Mar 2018

BRIEF-Protagonist Therapeutics Granted Two New US Patents For Peptide Drug Candidates PTG-100 And PTG-300

* PROTAGONIST THERAPEUTICS GRANTED TWO NEW US PATENTS FOR PEPTIDE DRUG CANDIDATES PTG-100 AND PTG-300 Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Protagonist Therapeutics Appoints Sarah Noonberg To Board

* PROTAGONIST THERAPEUTICS APPOINTS SARAH NOONBERG TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

14 Dec 2017

BRIEF-Protagonist Therapeutics Announces Final Phase 1 Study Results With Novel Hepcidin Mimetic, PTG-300

* PROTAGONIST THERAPEUTICS ANNOUNCES FINAL PHASE 1 STUDY RESULTS WITH NOVEL HEPCIDIN MIMETIC, PTG-300

14 Dec 2017

BRIEF-Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200

* Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200

09 Nov 2017

BRIEF-Protagonist Therapeutics Q3 ‍net loss per share $0.29​

* Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update

06 Nov 2017

Earnings vs. Estimates